Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.

ABSTRACT:

Context

Prostate cancer remains highly prevalent and has a poor clinical outcome once metastatic. Sipuleucel-T is an autologous cellular immunotherapy approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T treatment extends survival but is independent of traditional short-term markers of treatment response observed with chemotherapy and contemporary hormonal treatments. Therefore, it is essential that clinicians understand the mechanism of action of sipuleucel-T and how this can translate in the clinic.

Objective

This article aims to summarize the current knowledge of sipuleucel-T therapy and its effects in mCRPC.

Evidence acquisition

Relevant publications describing sipuleucel-T clinical data and information relating to im

SUBMITTER: Mulders PF 

PROVIDER: S-EPMC4456994 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature